Gardasil is a human papillomavirus (HPV) vaccine developed by Merck for prevention of disease caused by specific HPV strains. It was approved for medical use in the United States in 2006, and the original quadrivalent product was later replaced by Gardasil 9. Its prevention targets include HPV-related cancers and genital warts.
The FDA reversed its refusal to review Moderna’s mRNA flu vaccine application and accepted a revised filing with split age cohorts and a post-market study for adults over 65. The reversal came amid broader vaccine regulatory uncertainty and industry concern about unpredictable review timelines.
Merck received FDA approval in early February 2026 for KEYTRUDA and KEYTRUDA QLEX in PD-L1-positive platinum-resistant ovarian cancer. The decision marks the first approval of a PD-1 inhibitor regimen for this setting.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Merck partners with Mayo Clinic in a strategic research and development agreement to apply artificial intelligence and advanced analytics to drug discovery, integrating Mayo Clinic's clinical and genomic datasets with Merck's AI-enabled technologies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06142461 |
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System |
WITHDRAWN | PHASE2 |
| NCT04453241 |
Immunogenicity and Safety Study of NBP615 in Healthy Female |
COMPLETED | PHASE1/PHASE2 |
| NCT04022148 |
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years |
UNKNOWN | |
| NCT03998254 |
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03105856 |
FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program |
COMPLETED | PHASE4 |
| NCT02653118 |
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) |
ACTIVE_NOT_RECRUITING | |
| NCT02114385 |
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) |
COMPLETED | PHASE3 |
| NCT02087384 |
HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) |
COMPLETED | PHASE4 |
| NCT01914367 |
Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) |
COMPLETED | PHASE4 |
| NCT01741012 |
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients |
COMPLETED | PHASE1 |
